Back

Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

Deshmukh, M.; Sohai, D.; Obbad, K.; Park, K.; Milette, S.; Gu, P.; Nam, H.; Daniels, A.; Spasov, K.; Hurwitz, M.; Katz, S. G.; Flavell, R. A.; Anderson, K.; Bosenberg, M.; Micevic, G.

2026-07-06 immunology
10.64898/2026.07.03.736412 bioRxiv
Show abstract

Chronic stimulation of CD8 T cells within the tumor microenvironment (TME) induces a hypofunctional state characterized by diminished cytotoxicity and functionally impaired anti-tumor function, known as exhaustion. Exhaustion is associated with epigenetic changes that remain relatively stable despite interventions like immune checkpoint inhibition (ICI). Although epigenetic changes are potentially reversible, reports of therapeutic strategies to effectively restore function in exhausted CD8 T cells remain limited. Here, we report DNA methyltransferase 1 (DNMT1) inhibition (DNMT1i) in counteracting CD8+ T cell dysfunction during the anti-tumor response. We show that DNMT1i synergizes with ICI to rescue the tumor cell killing activity of chronically stimulated CD8 T cells in a melanoma model. DNMT1i mitigates transcriptional features of exhaustion while inducing a divergent effector program. DNMT1i attenuates the global increase in chromatin accessibility associated with exhaustion and enables epigenetic remodeling of the exhausted chromatin landscape upon restimulation. Finally, DNMT1i enhances the effector function of melanoma patient-derived tumor infiltrating lymphocytes after prolonged ex vivo expansion. These studies establish DNMT1 targeting as a promising strategy to counteract CD8 T cell exhaustion and potentiate ICI efficacy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.2%
12.7%
2
Cancer Immunology Research
35 papers in training set
Top 0.1%
11.7%
3
Nature Communications
5641 papers in training set
Top 19%
9.5%
4
Cell Reports
1498 papers in training set
Top 4%
7.2%
5
Immunity
67 papers in training set
Top 0.5%
4.0%
6
Cell Reports Medicine
153 papers in training set
Top 0.6%
4.0%
7
Journal of Experimental Medicine
119 papers in training set
Top 0.7%
3.5%
50% of probability mass above
8
Science Translational Medicine
127 papers in training set
Top 0.7%
3.2%
9
Journal of Clinical Investigation
179 papers in training set
Top 2%
3.1%
10
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 20%
2.6%
11
JCI Insight
277 papers in training set
Top 3%
2.4%
12
Cell Death & Disease
21 papers in training set
Top 0.2%
2.1%
13
Molecular Therapy
81 papers in training set
Top 0.8%
2.1%
14
EMBO Reports
263 papers in training set
Top 4%
1.7%
15
Cancer Research
130 papers in training set
Top 2%
1.7%
16
Science Advances
1243 papers in training set
Top 21%
1.7%
17
Science Immunology
88 papers in training set
Top 1%
1.5%
18
EMBO Molecular Medicine
95 papers in training set
Top 1%
1.5%
19
Science Signaling
65 papers in training set
Top 0.9%
1.3%
20
eLife
5828 papers in training set
Top 55%
1.3%
21
The Journal of Immunology
166 papers in training set
Top 2%
1.1%
22
OncoImmunology
24 papers in training set
Top 0.6%
1.0%
23
Cancer Cell
42 papers in training set
Top 1%
1.0%
24
npj Breast Cancer
23 papers in training set
Top 0.4%
1.0%
25
Nature Immunology
79 papers in training set
Top 2%
0.8%
26
Frontiers in Immunology
638 papers in training set
Top 10%
0.8%
27
Scientific Reports
3612 papers in training set
Top 75%
0.8%
28
Cell Communication and Signaling
51 papers in training set
Top 1%
0.8%
29
Theranostics
37 papers in training set
Top 1%
0.6%
30
Cancer Research Communications
51 papers in training set
Top 2%
0.6%